Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alexza appoints new senior VP and COO

This article was originally published in Scrip

Executive Summary

Alexza Pharmaceuticals – which develops treatments for central nervous system conditions including acute repetitive seizures and insomnia – has appointed Peter Schineller senior vice-president and chief commercial officer. Prior to joining Mountain View, California based-Alexza, Mr Schineller served as senior vice-president and general manager at Ventana Medical Systems, a diagnostic company owned by Roche. He will oversee Alexza's global commercialization efforts and strategies for its first approved product Adasuve (Staccatoloxapine) and will report to president and CEO, Thomas King.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC020761

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel